Abstract | BACKGROUND: The effect of topical mometasone for adenoid hypertrophy treatment is well established. Nevertheless, the influence of atopy on this treatment remains ill defined. OBJECTIVE: This study aims to compare the effects of topical mometasone furoate treatment on the adenoid tissue between atopic and nonatopic children. METHODS: Fifty-one children with obstructive respiratory complaints underwent a semistructured clinical questionnaire on nasal symptoms, prick test, and nasoendoscopy. Nasoendoscopic images were digitalized, and both adenoid and nasopharyngeal areas were measured in pixels; the relative adenoid/nasopharyngeal area was calculated. Patients were initially treated for 40 days with nasal saline solution. In a subsequent 40-day period, topical mometasone furoate (total dose, 100 μg/day) was used. RESULTS: Topical mometasone significantly improved nasal obstruction, snoring, and apnea and also significantly reduced the adenoid tissue area related to the nasopharynx (p < 0.0001). Treatment with this glucocorticoid was not influenced by atopy, neither for symptoms nor for adenoid area. CONCLUSION: Topical mometasone furoate significantly reduced the adenoid tissue area and led to a supplementary improvement of nasal symptoms. This improvement was similar for atopic and nonatopic patients.
|
Authors | Renato M Rezende, Flávia S Amato, Aline P Barbosa, Ulissis P Menezes, Patrícia Rezende, Virgínia P L Ferriani, Wilma T Anselmo-Lima, Fabiana C P Valera |
Journal | American journal of rhinology & allergy
(Am J Rhinol Allergy)
2015 Jan-Feb
Vol. 29
Issue 1
Pg. 54-6
ISSN: 1945-8932 [Electronic] United States |
PMID | 25590321
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Pregnadienediols
- Mometasone Furoate
|
Topics |
- Adenoids
(pathology)
- Administration, Topical
- Anti-Inflammatory Agents
(therapeutic use)
- Child
- Female
- Humans
- Hypertrophy
- Male
- Mometasone Furoate
- Pregnadienediols
(administration & dosage, therapeutic use)
|